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Background: The ratio of glycated albumin to glycated hemoglobin (GA/A1c) is known to be elevated in subjects with type 2 di-
abetes mellitus (T2DM) who had decreased insulin secretion. Additionally, the carotid intima media thickness (IMT) is greater 
in T2DM patients with higher GA/A1c ratios. We investigated whether increased GA/A1c ratio and IMT are also associated in 
type 1 diabetes mellitus (T1DM), which is characterized by lack of insulin secretory capacity.
Methods: In this cross-sectional study, we recruited 81 T1DM patients (33 men, 48 women; mean age 44.1±13.0 years) who un-
derwent carotid IMT, GA, and HbA1c measurements.
Results: The mean GA/A1c ratio was 2.90. Based on these results, we classified the subjects into two groups: group I (GA/A1c 
ratio <2.90, n=36) and group II (GA/A1c ratio ≥2.90, n=45). Compared with group I, the body mass indexes (BMIs), waist cir-
cumferences, and IMTs were lower in group II. GA/A1c ratio was negatively correlated with BMI, urine albumin to creatinine 
ratio (P<0.001 for both), and both the mean and maximal IMT (P=0.001, both). However, after adjusting the confounding fac-
tors, we observed that IMT was no longer associated with GA/A1c ratio.
Conclusion: In contrast to T2DM, IMT was not significantly related to GA/A1c ratio in the subjects with T1DM. This suggests 
that the correlations between GA/A1c ratio and the parameters known to be associated with atherosclerosis in T2DM could be 
manifested differently in T1DM. Further studies are needed to investigate these relationships in T1DM.
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INTRODUCTION
Although glycated albumin (GA) was initially viewed as an ad-
junct to glycated hemoglobin (HbA1c) in initial assessments 
and then as a part of continuing diabetes care, recently mount-
ing evidence has demonstrated the contributing roles of GA to 
the pathogenesis of atherosclerosis [1-3]. In accordance with 
these reports, we recently demonstrated that GA has athero-
genic effects that lead to the development of atherosclerosis in 
subjects with type 2 diabetes mellitus (T2DM) based on cross-
sectional and longitudinal analyses [4-6]. In those studies, the 
serum GA level and the ratio of GA to HbA1c (GA/A1c) were 
identified as potential surrogate parameters that are associated 
with or predict the progression of atherosclerosis in T2DM 
subjects [5,6]. It has been demonstrated that the GA/A1c ratio 
of T2DM increases in parallel with decreasing insulin secretory 
function [7], which results in elevated postprandial blood glu-
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tance and its related inflammatory biomarkers are associated 
with the risk factors of atherosclerosis and/or atherosclerosis 
itself, the GA/A1c ratio of subjects with T2DM might be asso-
ciated with intima media thickness (IMT) as an additional 
mechanism.
 In contrast to the results of the study of T2DM, the recently 
published Diabetes Control and Complications Trial (DCCT)/
Epidemiology of Diabetes Interventions and Complications 
study found no association between GA and cardiovascular 
events in subjects with type 1 diabetes mellitus (T1DM) [9]. 
While the reason for this finding has not yet been elucidated, it 
may likely be due to the differences in pathologic mechanisms 
between T2DM and T1DM. Unlike T2DM, there is a dearth of 
insulin secretion in T1DM, which might result in different cor-
relations between GA/A1c ratio and various biomarkers as 
compared with T2DM. Therefore, to confirm this hypothesis, 
we attempted to identify the associations between GA/A1c ra-
tio and various other known risk factors for cardiovascular dis-




This study was a retrospective, cross-sectional investigation of 
T1DM patients. We included T1DM patients who were regis-
tered in the Severance Hospital Diabetes Registry from August 
2011 to January 2013. T1DM was defined by a glucose level 
greater than 200 mg/dL, clinical characteristics, positivity for 
antiglutamic acid decarboxylase, and a decreased C-peptide 
level (below 0.6 ng/mL) at the initial visit. T1DM patients were 
included in the study if they satisfied the following criteria: (1) 
aged 20 to 75 years; (2) had undergone carotid IMT measure-
ments; (3) had been tested for both HbA1c and GA every 3 or 
6 months; and (4) no documented symptoms, signs, or history 
of atherosclerotic vascular disease (e.g., cerebrovascular acci-
dents, angina, myocardial infarction, or peripheral vascular 
disease). The exclusion criteria were as follows: (1) hematolog-
ical and/or malignant disease; (2) chronic kidney disease (cre-
atinine >1.5 mg/dL); and (3) plasma aspartate transaminase 
(AST) and/or alanine transaminase (ALT) levels 2-fold higher 
than the upper limit of the normal range. Hypertension was 
defined as two documented measurements of systolic blood 
pressure above 140 mm Hg and/or diastolic blood pressure 
above 90 mm Hg according to the JNC 7 Report [10] or pres-
ent treatment with antihypertensive drugs. Dyslipidemia was 
defined by serum concentrations of total cholesterol ≥240 mg/
dL [11], triglyceride concentrations exceeding 150 mg/dL, or 
current treatment with lipid-lowering agents.
 We performed routine screening laboratory tests and IMT 
measurements for 86 patients, of whom we excluded five pa-
tients for age differences (n=2) and chronic kidney disease 
(n=3). We calculated the GA/A1c ratios and classified the re-
maining patients into two groups based on their mean value of 
this measurement (group I, GA/A1c <2.90; and group II, GA/
A1c ≥2.90). This study protocol was approved by the Institu-
tional Review Board of Severance Hospital (No. 2013-0917-
001), which waived the requirement of informed consent.
Laboratory assessment
Blood samples were collected from subjects after overnight 
fasts. The fasting glucose and 2-hour postprandial glucose after 
a conventional meal were measured. Plasma glucose was mea-
sured using the glucose oxidase method. Plasma total choles-
terol, triglyceride, high density lipoprotein cholesterol, blood 
urea nitrogen, creatinine, AST, and ALT levels were assayed us-
ing routine procedures with a Hitachi 7600 auto analyzer (Hit-
achi Instruments Service, Tokyo, Japan). Low density lipopro-
tein cholesterol was calculated using the Friedewald equation. 
Serum C-peptide levels were measured in duplicate with im-
munoradiometric assays (Beckman Coulter, Fullerton, CA, 
USA). Urine albumin to creatinine ratio (ACR) was calculated 
using the results of urine microanalysis (Hitachi 7180; Hitachi 
Instruments Service). Serum GA was determined by an enzy-
matic method utilizing an albumin-specific proteinase, ket-
amine oxidase, albumin assay reagents (LUCICA GA-L; Asahi 
Kasei Pharma Co., Tokyo, Japan), and a Hitachi 7699 P module 
auto-analyzer; the coefficient of variation (CV) for these mea-
surements was 1.43%. Serum HbA1c was measured via high-
performance liquid chromatography using a Variant II Turbo 
system (BioRad Laboratories, Hercules, CA, USA). HbA1c 
measurements were standardized to the reference method ac-
cording to the DCCT and the National Glycohemoglobin Stan-
dardization Program standards [12]. The reference interval was 
20 to 40 mmol/mol (4.0% and 6.0%) for HbA1c; for GA, this 
interval was 11.0% to 16.0%.
Measurement of IMT
Ultrasound measurements of the common carotid arteries 
were obtained with two sonographers using an Aloka Pro-
Sound ALPHA 10 (Hitachi) with a 13 MHz linear probe. All 
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measurements were collected with the patients in the supine 
position with their heads elevated to 45° and tilted to either side 
at 30° depending on the side being examined. We also per-
formed bilateral B-mode examinations 1.5 cm proximal to the 
carotid bifurcation on the far wall of the common carotid artery. 
IMT was defined as the distance between the media-adventitia 
interface and the lumen-intima interface. The average IMT was 
defined as the mean of the computer-based points in the region, 
and the maximum IMT was defined as the IMT at the maxi-
mum point of the region [13]. We assessed the reproducibility 
of the carotid IMT measurements and found an interobserver 
CV of 2.11% and a day-to-day CV of 2.06%. Plaques were de-
fined according to the Mannheim consensus [14] and were di-
agnosed when the vessel wall thickness was greater than 1.5 
mm or when it was at least 0.5 mm or 50% thicker than the sur-
rounding wall.
Statistical analyses
All statistical analyses were performed with PASW version 18.0 
(SPSS, Chicago, IL, USA). The Kolmogorov-Smirnov test was 
performed to determine whether the data were normally dis-
tributed, and this test confirmed that the GA/A1c ratio data 
were normally distributed. Continuous variables with normal 
distributions are expressed as means±standard deviation, and 
variables with non-normal distributions are expressed as the 
medians (with tertile ranges). Discrete variables are expressed 
as percentages. Statistical comparisons between groups that 
were divided according to the GA/A1c ratios were performed 
using Student t-tests or Mann-Whitney U tests. Spearman cor-
relations were used to determine the relationships between 
GA/A1c ratio and the continuous variables. Multiple regres-
sion analysis was used to estimate multiple correlations of GA/
A1c ratio with IMT and other clinical and laboratory risk fac-
tors for atherosclerosis. Comparisons yielding P<0.05 were 
considered significant. 
RESULTS 
A total of 81 subjects (33 men and 48 women; mean age 44.1± 
13.0 years) participated in this study. Table 1 shows the baseline 
clinical and laboratory characteristics of patients. The mean 
durations of diabetes and body mass index (BMI) were 13.0± 
7.5 years and 22.6±3.0 kg/m2, respectively. The fasting C-pep-
tide level was 0.16±0.2 ng/mL. The serum GA and HbA1c lev-
els were 26.2%±9.9%, and 8.7%±2.0%, respectively. The mean 
GA/HbA1c ratio was 2.90±0.8. Among these patients, 46 had 
been diagnosed with hypertension, and 51 had dyslipidemia. 
Antiplatelet agents had been prescribed to 31 patients, and all 
patients were dependent on insulin. The daily dose of insulin 
was 53.9±41.2 units/day. Twenty-three patients were being co-
treated with oral hypoglycemic agents.
 Given that GA/A1c ratio is associated with glucose fluctua-
tions, we divided the patients into two groups according to the 
Table 1. Baseline characteristics of the study population




≥2.90 (n=45) P value
a
Age, yr 44.1±13.0 45.7±12.9 42.6±13.0 0.278
Male sex 33 (40.7) 18 (50.0) 15 (33.3) 0.346
DM duration, yr 13.0±7.5 13.1±7.6 12.9±7.5 0.907
Smoking 10 (12.3) 6 (16.7) 4 (8.9) 0.266
BMI, kg/m2 22.6±3.0 23.9±2.8 21.4±2.7 <0.001
WC, cm 80.1±9.3 83.7±9.3 77.2±8.4 0.003
SBP, mm Hg 123.2±15.8 125.4±14.1 121.2±17.2 0.238
DBP, mm Hg 74.7±9.8 76.0±10.3 74.1±9.4 0.546
Cholesterol,
   mg/dL
179.1±40.5 181.3±39.7 177.1±41.6 0.639
TG, mg/dL 98.5±70.6 112.9±87.1 84.8±47.2 0.080
HDL-C, mg/dL 57.3±16.4 54.6±14.7 59.8±17.7 0.159
LDL-C, mg/dL 100.7±32.6 103.3±32.0 98.3±33.5 0.492
Fasting glucose, 
   mg/dL
172.9±92.9 165.3±79.3 180.1±104.3 0.477
Postprandial
    glucose, mg/dL
230.0±113.8 208.8±96.7 251.9±126.9 0.111
Fasting C-pep- 
   tide, ng/mL
0.16±0.2 0.22±0.3 0.12±0.2 0.123
Glycoalbumin, % 26.2±9.9 21.0±5.0 30.0±10.4 <0.001
HbA1c, % 8.7±2.0 8.5±1.8 8.9±2.2 0.458
GA/A1c ratio 2.90±0.8 2.47±0.4 3.50±0.7 <0.001
Urine ACR, 
   µg/mg
345.1±897.3 576.9±1,216.5 165.5±480.6 0.083
Mean IMT, mm 0.60±0.1 0.64±0.1 0.56±0.1 0.003
Max IMT, mm 0.71±0.2 0.77±0.2 0.66±0.2 0.001
Values are presented as mean±standard deviation or number (%). 
GA/A1c, glycated albumin to glycated hemoglobin ratio; DM, diabe-
tes mellitus; BMI, body mass index; WC, waist circumference; SBP, 
systolic blood pressure; DBP, diastolic blood pressure; TG, triglycer-
ide; HDL-C, high density lipoprotein cholesterol; LDL-C, low density 
lipoprotein cholesterol; ACR, albumin to creatinine ratio; IMT, inti-
ma media thickness.
aP value of the comparisons between group I and II.
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mean GA/A1c ratio (group I, GA/A1c <2.90; group II, GA/A1c 
≥2.90). The BMIs and waist circumferences of group I were sig-
nificantly higher than those of group II (23.9±2.8 kg/m2 vs. 
21.4±2.7 kg/m2 and 83.7±9.3 cm vs. 77.2±8.4 cm; P<0.001, 
P=0.003, respectively). We noted that the serum HbA1c level 
was higher in group II, but this difference was not statistically 
significant (8.5%±1.8% vs. 8.9%±2.2%; P=0.458). However, 
the serum GA levels were significantly different between group 
I and II (21.0%±5.0% vs. 30.0%±10.4%, respectively; P<0.001), 
explaining the much higher GA/A1c ratio in group II (3.34± 
0.4) compared to group I (2.47±0.4, P<0.001). Furthermore, 
group II exhibited significantly lower mean and maximum IMT 
values compared to group I. These results suggest that T1DM 
patients with greater glucose fluctuations had lower IMTs, 
which contrasts to the results that have been observed in T2DM 
patients. The numbers of patients who were taking antihyper-
tensive medications were 18 (50.0%) in group I and 17 (37.8%) 
in group II (chi-square, P=0.270). Statins had been prescribed 
for 18 patients (50.0%) in group I and 12 patients (26.7%) in 
group II (chi-square, P=0.031). Half of the patients (18, 50.0%) 
in group I and 13 (28.9%) patients in group II were being treat-
ed with antiplatelet agents (chi-square, P=0.052).
 Table 2 illustrates the relationships of GA/A1c ratio with car-
diovascular risk factors and glycemic indices. In all subjects, 
higher GA/A1c ratios were positively associated with higher 
postprandial glucose levels (P=0.008). In contrast, this ratio 

































Fig. 1. (A, B) Relationships of body mass index (BMI) with glycated albumin to glycated hemoglobin (GA/A1c) ratio and intima 
media thickness (IMT) in type 1 diabetes mellitus patients. (A) There was a positive association between BMI and IMT (r=0.331, 
P=0.005). (B) In contrast, BMI and GA/A1c were negatively related (r=–0.448, P<0.001).









β P value β P value β P value
Age –0.176 0.116 0.013 0.935 –0.284 0.072
Duration –0.023 0.839 –0.027 0.869 –0.087 0.587
Smoking –0.049 0.663 0.177 0.274 –0.205 0.199
BMI –0.463 <0.001 –0.014 0.933 –0.500 0.001
Waist circumference –0.390 0.001 0.077 0.688 –0.444 0.005
SBP –0.145 0.203 0.182 0.267 –0.204 0.207
DBP –0.082 0.473 0.036 0.829 0.022 0.895
Cholesterol –0.070 0.533 –0.298 0.061 0.193 0.227
Triglycerides –0.161 0.154 –0.124 0.447 0.293 0.066
HDL-C 0.214 0.056 0.096 0.557 0.150 0.356
LDL-C –0.105 0.353 –0.327 0.039 0.241 0.134
Fasting glucose 0.060 0.614 0.119 0.503 0.154 0.350
Postprandial glucose 0.347 0.008 0.355 0.054 0.345 0.078
Fasting C-peptide –0.425 <0.001 –0.455 0.007 –0.036 0.817
Urine ACR –0.403 <0.001 –0.657 <0.001 0.176 0.279
Mean IMT –0.351 0.001 –0.023 0.886 –0.360 0.023
Max IMT –0.376 0.001 –0.130 0.422 –0.333 0.033
GA/A1c, glycated albumin to glycated hemoglobin ratio; BMI, body 
mass index; SBP, systolic blood pressure; DBP, diastolic blood pres-
sure; HDL-C, high density lipoprotein cholesterol; LDL-C, low den-
sity lipoprotein cholesterol; ACR, albumin to creatinine ratio; IMT, 
intima media thickness.
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BMI (P<0.001), waist circumference (P=0.001), urine ACR 
(P<0.001), and both mean and maximal IMTs (P=0.001 for 
both). However, the negative relationship between GA/A1c ra-
tio and IMT was only statistically significant in group II (GA/
A1c ≥2.90). We also analyzed the relationships of BMI with 
GA/A1c ratio and IMT; BMI was positively associated with 
IMT and negatively associated with GA/A1c ratio (Fig. 1).
 The patients were further segregated into the following 
three categories according to urine ACR levels: category I, nor-
mal (<30.0 µg/mg); category II, microalbuminuria (30.0 to 
299.9 µg/mg); and category III, macroalbuminuria (≥300.0 µg/
mg). Consequently, we observed that the GA/A1c ratio of the 
category II patients was significantly higher than those of the 
other groups, but the mean and maximum IMTs were similar 
across all groups (Appendix Table 1). Appendix Fig. 1 illus-
trates the associations of urine ACR with GA/A1c ratio and 
IMT; in this figure, the negative correlation between GA/A1c 
ratio and urine ACR (r=–0.403, P<0.001) and the positive cor-
relation between IMT and urine ACR (r=0.255, P=0.032) can 
be observed.
 A multiple regression analysis was used to investigate the re-
lationships between GA/A1c ratio and the other significant 
variables as selected from Table 2; these variables included 
well-known cardiovascular risk factors (i.e., BMI and urine 
ACR), postprandial glucose, and IMT. Due to redundancy, we 
omitted waist circumference from the obesity-related variables. 
In all patients, BMI, postprandial glucose, and urine ACR were 
significantly related to GA/A1c ratio (Table 3). However, IMT 
did not exhibit a significant relationship with GA/A1c ratio in 
the subjects with T1DM. To assess the associations between ca-
rotid IMT and the other risk variables (i.e., age, sex, BMI, post-
prandial glucose, urine ACR, and GA/A1c ratio), another mul-
tiple regression analysis was performed and indicated that age 
was the only factor that was statistically associated with IMT in 
the subjects with T1DM (Appendix Table 2). 
DISCUSSION
Previous studies have demonstrated that elevated GA and GA/
A1c ratios in T2DM are implicated not only in increased glyce-
mic variability [8,15-17], but also in the development of ath-
erosclerosis [2,5,6,18]. However, the associations of increased 
GA and GA/A1c ratio with atherosclerosis are not well under-
stood in T1DM, in which not only insulin resistance but also 
absolute insulin deficits are the primary mechanisms of disease 
pathology [19-22]. Many questions remain to be answered re-
garding whether a simple and accurate glycemic index that 
covers glycemic variability exists and if so, whether such an in-
dex could successfully reflect glycemic variability in clinical 
practice. Based on the hypothesis that the GA/A1c ratio is a 
simple tool for the evaluation of glucose fluctuation regardless 
of the type of diabetes, we investigated the relationship between 
GA/A1c ratio and carotid atherosclerosis in subjects with 
T1DM.
 This study has three main findings. Firstly, those with higher 
GA/A1c ratios had lower BMIs. This inverse correlation be-
tween glycemic variability and BMI has previously been report-
ed in T1DM and insulin-treated T2DM patients [23,24]. Due to 
the retrospective nature of this study, we cannot completely ex-
plain the negative association between high GA/A1c ratios (in-
cluding poor glycemic control) and low BMIs. However, con-
sidering the distinct pathophysiologic mechanisms of T1DM 
compared to those of T2DM (i.e., relative insulin secretory dys-
function in conjunction with increased insulin resistance plays 
a major role in the development of T2DM [22]), we additionally 
showed that increased BMI does not affect the onset and devel-
opment of T1DM. One plausible explanation for the negative 
association between GA/A1c ratio and BMI might be the limit-
ed body reservoir for exogenous insulin-mediated glucose up-
take [24]. In this regard, we postulated that decreased body 
mass might be the limiting factor in the facilitation of glucose 
uptake inside of cells in the setting of external insulin injection.
 Second, only age was found to predict the development of 
carotid IMT in the multiple regression analysis; i.e., in this 
study, carotid IMT was not statistically influenced by tradition-
ally important risk factors for cardiovascular diseases, such as 
Table 3. Risk factors that independently affected GA/HbA1c 
ratio (GA/A1c as a dependent variable)
Variable Standard error
Standardized 
coefficient β P value
Age 0.006 0.010 0.106
Sex 0.130 0.026 0.844
BMI 0.024 –0.091 <0.001
Postprandial glucose 0.001 0.001 0.026
Urine ACR 0.000 0.000 0.002
IMT max 0.451 –0.583 0.202
GA/A1c, glycated albumin to glycated hemoglobin ratio; BMI, body 
mass index; ACR, albumin to creatinine ratio; IMT, intima media 
thickness.
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high BMI and urine ACR (Appendix Table 2). Although it is 
possible that the association between high BMI with athero-
sclerosis was mediated by unknown pathophysiologic mecha-
nisms in this T1DM population, low mean BMI (22.6±3.0 kg/
m2) and relatively young age (44.1±13.0 years) might account 
for this result. These findings suggest that the development of 
atherosclerosis in T1DM might be primarily caused not by in-
sulin resistance (i.e., high BMI) but by the aging process. In this 
regard, the positive association between BMI and carotid IMT 
in our study might not be of the clinical relevance.
 Finally, GA/A1c ratio was not related to carotid IMT in T1DM. 
In previous studies conducted with subjects with T2DM, we have 
demonstrated that GA/A1c ratio, which reflects glycemic vari-
ability, positively, and significantly affects the development and 
progression of atherosclerosis in T2DM in which the underlying 
pathophysiologic mechanism of insulin resistance plays a major 
role in the development and aggravation of both T2DM and ath-
erosclerosis [5,6]. Based on these findings, we hypothesized that 
glycemic variability might play a different and important role in 
the development of atherosclerosis in T1DM in which absolute 
insulin deficiency is the central mechanism of hyperglycemia. 
Indeed, our findings emphasize insulin resistance is an impor-
tant factor in the development of atherosclerosis in T2DM but 
not in T1DM.
 This study had the following limitations. First, this was a 
cross-sectional, retrospective study. Thus, this study failed to 
examine insulin resistant markers and utilize the gold standard 
tool of continuous glucose monitoring for evaluating glucose 
variability to determine the relationship between glucose fluc-
tuation and carotid atherosclerosis in T1DM subjects. Further-
more, the cross-sectional nature of this study precluded the 
definite establishment of the statistical correlation between 
GA/A1c ratio and BMI in subjects with T1DM. Second, as dis-
cussed above, we were unable to provide a clear explanation of 
the association between high GA/A1c ratio and low BMI. 
Lastly, GA, and GA/A1c ratio might not have accurately re-
flected the actual glucose variability.
 In this study, we evaluated the relationship between GA/A1c 
ratio, which reflects glucose fluctuation, and carotid atheroscle-
rosis in Korean T1DM subjects. IMT was not significantly re-
lated to GA/A1c ratio in subjects with T1DM. Given the differ-
ent pathophysiologic mechanisms of T1DM and T2DM, we 
suspect that glycemic variability plays a role in the develop-
ment of carotid atherosclerosis only in the setting of insulin re-
sistance. However, larger, prospective, longitudinal, and con-
trolled studies are needed to investigate the relationship be-
tween glycemic variability as reflected by GA/A1c ratio and the 
progression of atherosclerosis in subjects with T1DM and in-
sulin resistance.
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Category IIb  
(n=15)
Category IIIc  
(n=13) P value
GA/A1c ratio 3.00±0.5 3.11±0.4 2.49±0.8 0.015
Mean IMT, mm 0.57±0.1 0.63±0.1 0.65±0.1 0.102
Max IMT, mm 0.67±0.1 0.73±0.2 0.80±0.2 0.061
Values are presented as mean±standard deviation.
GA/A1c, glycated albumin to glycated hemoglobin ratio; IMT, intima 
media thickness; ACR, albumin to creatinine ratio.
aCategory I, normal (urine ACR <30.0 µg/mg), bCategory II, microal-
buminuria (urine ACR 30.0 to 299.9 µg/mg), cCategory III, macroal-































Appendix Fig. 1. (A, B) Correlations of urine albumin to creatinine ratio (ACR) with glycated albumin to glycated hemoglobin 
(GA/A1c) ratio and intima media thickness (IMT). There was a negative correlation between urine ACR and GA/A1c ratio (A, 
r=–0.403, P<0.001), while urine ACR and IMT were positively related (B, r=0.255, P=0.032).
Appendix Table 2. Multiple regression analysis of IMT and 
cardiovascular risk factors (IMT as a dependent variable)
Variable Standard error
Standardized 
coefficient β P value
Age 0.003 0.012 <0.001
Sex 0.068 –0.001 0.994
BMI 0.014 –0.017 0.241
Postprandial glucose 0.000 0.000 0.491
Urine ACR 0.000 0.000 0.734
GA/A1c ratio 0.068 –0.062 0.375
IMT, intima media thickness; BMI, body mass index; ACR, albumin 
to creatinine ratio; GA/A1c, glycated albumin to glycated hemoglo-
bin ratio.
